Anish Bhatnagar - 25 Jan 2024 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: SLNO
Reported as of: 25 Jan 2024
Net transaction value: -$122,054
SEC form: 4
Accepted by SEC: 29 Jan 2024, 17:42:33 UTC
Prior SEC filing: 08 Jan 2024
Next SEC filing: 03 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ Anish Bhatnagar

Key filing fact

Anish Bhatnagar filed Form 4 for SOLENO THERAPEUTICS INC (SLNO) on 29 Jan 2024.

Key facts

This page summarizes Anish Bhatnagar's Form 4 filing for SOLENO THERAPEUTICS INC (SLNO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 29 Jan 2024, 17:42.

Change

Previous filing in this sequence was filed on 08 Jan 2024.
Current net transaction value: -$122,054.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLNO transaction

Common Stock

Sale

Transaction value: $122,054
Shares: -2,527
Change %: -1.4%
Price: $48.30
Shares after: 171,770
Date: 25 Jan 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

Footnote F2

Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.